CD33 and acute myeloid leukemia: The heterogeneity of target antigen expression also poses challenges in the treatment of single‐cell cancers like acute myeloid leukaemia (AML) (Saito & Nakazawa, 2024). The variability in antigen expression and the immunosuppressive TME hinder the development of effective CAR T cells. While various targets, including CD33, NKG2D, CD123, CLL‐1 and CD7, have been investigated, with some showing promise in clinical trials, especially those targeting CLL‐1 or CD123, overcoming these obstacles remains an active area of research (Saito & Nakazawa, 2024).